Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03294694
Title Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

peritoneum cancer

Her2-receptor negative breast cancer

ovarian cancer

fallopian tube cancer

Therapies

Fulvestrant + Ribociclib + Spartalizumab

Ribociclib + Spartalizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.